Combination Therapy for Glaucoma

Brief Description

An innovative small molecules therapy that significantly lowers intraocular pressure in glaucoma patients, offering neuroprotection and addressing trabecular meshwork fibrosis.

Full Description

This technology encompasses a synergistic combination of sodium 4-phenylbutyrate (PBA) and Tauroursodeoxycholic acid (TUDCA) for the treatment of glaucoma. This approach not only lowers intraocular pressure (IOP) more effectively than current medications but also acts as a direct neuroprotectant and counters fibrosis in the trabecular meshwork (TM), potentially increasing the success rate of IOP-lowering surgeries and interventions.

Suggested uses

• Primary and adjunctive therapy for all forms of glaucoma. 
• Preventive treatment for high-risk individuals to protect against neuronal loss. 
• Complementary therapy to enhance the success rate of IOP-lowering surgeries and devices.

Advantages

• Significantly lowers IOP by up to 40%, outperforming current glaucoma drugs.
• Reduces IOP by targeting trabecular meshwork pathology in glaucoma.
• Offers direct neuroprotection to prevent neuronal loss associated with glaucoma.
• Addresses and potentially reverses trabecular meshwork fibrosis, a common cause of surgical failure in glaucoma treatment.
• Can be used alone or in conjunction with existing IOP-lowering medications, offering a versatile treatment option.
• Based on FDA-approved molecules for other conditions, potentially easing the regulatory pathway for glaucoma treatment.
• Excellent proof-of-concept data in preclinical mouse and human models of glaucoma.

Patent Status

Patent Pending